SCM
ANTX icon

Stonepine Capital Management’s AN2 Therapeutics ANTX Stock Holding History

Stonepine Capital Management’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.44M Buy
713,845
+86,177
+14% +$178K 0.98% 16
2025
Q4 		$716K Buy
627,668
+63,755
+11% +$74.5K 0.52% 44
2025
Q3 		$716K Buy
563,913
+19,419
+4% +$22.2K 0.58% 33
2025
Q2 		$577K Buy
+544,494
New +$649K 0.57% 39
2025
Q1 		– Sell
-196,732
Closed -$271K – 69
2024
Q4 		$271K Buy
+196,732
New +$239K 0.22% 45

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Stonepine Capital Management's ANTX Position: Q1 2026 in Review

Stonepine Capital Management increased its AN2 Therapeutics (ANTX) stake by 14% in Q1 2026, buying an estimated $178K and bringing the position to 713,845 shares worth $2.44M. The position accounts for 0.98% of the portfolio, ranked #16.

Stonepine Capital Management first reported a position in ANTX in Q4 2024 and has held it in 5 quarters since. 52 funds tracked by Wall St. Rank hold ANTX as of Q1 2026.

  • Stonepine Capital Management held 713,845 shares of AN2 Therapeutics worth $2.44M as of Q1 2026.
  • Stonepine Capital Management bought 86,177 AN2 Therapeutics shares in Q1 2026, an estimated $178K.
  • AN2 Therapeutics made up 0.98% of Stonepine Capital Management's portfolio in Q1 2026, its #16 holding.
  • Stonepine Capital Management first reported a position in AN2 Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • 52 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q1 2026.

Based on Stonepine Capital Management's 13F filing for Q1 2026, filed 14 May 2026.